Finn
IRON Biotechnology · Clinical-stage · Hematology · Rare disease · Thesis updated November 15, 2026

APOLLO success clears the path to an FDA decision

01 Running thesis

Clinical risk removed, regulatory wait begins

Disc Medicine is moving closer to commercial reality. Its lead drug, bitopertin, was previously derailed by an FDA Complete Response Letter in early 2026. The agency demanded clear clinical proof that the drug improved sunlight tolerance for patients with rare blood disorders known as EPP and XLP.

The company delivered that proof in October 2026. The Phase 3 APOLLO trial met both primary endpoints, removing the biggest clinical overhang on the stock. Management now plans to resubmit the New Drug Application by the end of 2026, setting up a potential traditional FDA approval by mid-2027.

Disc capitalized on the positive data by raising nearly $486 million. This extends the cash runway into 2030, allowing the company to aggressively fund its earlier-stage pipeline, including DISC-0974 and DISC-3405.

The bull case is that bitopertin approval is now highly likely, transforming the company into a commercial operation. The bear case focuses on what happens after launch. The composition of matter patent for bitopertin expires in 2026, meaning investors must carefully watch the intellectual property strategy to see how long the commercial window will actually last.

Nov 2026▲Disc reported positive topline APOLLO results for bitopertin and raised nearly $486 million, extending its cash runway into 2030.
Jul 2026▲The FDA clarified in a Type A meeting that the ongoing Phase 3 APOLLO trial can support traditional approval. Interim RALLY-MF data also showed promising anemia responses.
May 2026▲Disc completed APOLLO enrollment with 183 patients, which makes the Q4 2026 bitopertin data timing firmer. The company also said it expects a potential FDA decision by mid-2027 if the data support resubmission.
Feb 2026▼The FDA issued a Complete Response Letter for bitopertin and rejected the accelerated approval path. The lead asset now depends on APOLLO proving clinical benefit.
Nov 2025▲Disc submitted the bitopertin NDA and received a priority review voucher. A large financing also extended the runway into 2029, though DISC-0974 CKD data added uncertainty.
Aug 2025▲The company gave a clearer October 2025 NDA target for bitopertin after FDA feedback. It also initiated the DISC-3405 Phase 2 PV trial and kept a strong cash position.
May 2025▲Disc initiated the APOLLO confirmatory trial, keeping the bitopertin plan on schedule at that time. Cash runway into 2028 reduced near-term financing pressure.
Feb 2025▲The company guided to a second half 2025 NDA filing for bitopertin. A January 2025 financing extended expected runway into 2028.
02 Business model

Funded science, waiting for sales

Disc is a clinical-stage biotech company with no product revenue. The business is built entirely on drug discovery and clinical trials, funded by cash raised from stock sales and debt.

If the FDA approves bitopertin in mid-2027, Disc will begin transitioning into a commercial operation. Revenue would then come from direct product sales or regional partnerships. Until then, the company burns cash to run trials and prepare for launch.

The recent $486 million public offering removed near-term financing pressure. The company expects its current cash balance to fund operations into 2030. Expenses remain heavily weighted toward research and development.

03 Product portfolio

Shots on blood biology

Growth engine

Bitopertin for EPP and XLP

The lead asset achieved positive Phase 3 APOLLO results in October 2026. Disc plans to resubmit the NDA by the end of 2026 for a potential mid-2027 approval.

Option

Bitopertin for DBA

Disc is also testing bitopertin for Diamond-Blackfan Anemia in a Phase 2 trial. This is a smaller opportunity compared to the EPP and XLP markets.

Option

DISC-0974 for anemia of myelofibrosis

This antibody is designed to lower hepcidin. Phase 2 RALLY-MF data showed promising responses, with more updates expected soon.

Option

DISC-3405 for PV and SCD

This antibody targets TMPRSS6 to raise hepcidin. It is currently in Phase 2 testing for PV and Phase 1b for sickle cell disease.

04 Business segments

One segment, expense-heavy

Research and development expense70%growing fast
Selling, general and administrative expense30%growing fast

Disc reports one business segment: discovery and development of hematologic therapeutics. Because it has no product revenue, the mix below uses operating expenses, with R&D as the clear center of spending.

05 Risk factors

What could break

FDA asks for more work

High impact · Medium odds

Even with positive APOLLO data, the FDA could ask for extra analyses, longer follow-up, or a narrower label. That would delay revenue and raise costs.

We watchAny change to the planned mid-2027 FDA decision timeline.

Bitopertin patent overhang

High impact · High odds

The composition of matter patent for bitopertin expires in 2026. Even if Disc wins approval in mid-2027, investors need to know what exclusivity protects the product after launch.

We watchAny disclosure on regulatory exclusivity, Orange Book listings, settlement risk, or generic competition.

Pipeline fails to deliver

Medium impact · Medium odds

Disc is spending heavily on DISC-0974 and DISC-3405 to reduce its dependence on bitopertin. If those programs produce weak data, the company remains a single-product story.

We watchData readouts for RALLY-MF, RESTORE-PV, and the sickle cell disease trial.
06 Quick answers

In one breath

Does Disc Medicine have revenue?

No. The company has not generated product revenue yet. Future revenue depends on FDA approval for bitopertin and successful commercialization.

What were the APOLLO results?

In October 2026, Disc announced positive Phase 3 APOLLO results for bitopertin, meeting both primary endpoints. This clears the way for an NDA resubmission.

How long is the cash runway?

Following a massive $486 million public offering in October 2026, the company expects its cash balance to fund operations into 2030.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Disc Medicine Q3 2026 Form 10-Q
  2. Disc Medicine Q2 2026 Form 10-Q
  3. Disc Medicine Q1 2026 Form 10-Q
08 Explore the industry

Comparable Biotechnology companies

Companies near Disc Medicine, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today